AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
ASTRAZENECA PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026
- Market cap
- $255.76B
- P/E (TTM)
- 25.1
- Dividend yield
- 1.91%
ASTRAZENECA PLC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duaklir | – | – | – | – | – | – | $77.00M | $95.00M | $79.00M | $63.00M | – | – |
| Movantik/Moventig | – | – | – | – | – | – | – | $109.00M | $122.00M | $91.00M | – | – |
| Tagrisso | – | – | – | – | $5.02B | $4.33B | $3.19B | $1.86B | $955.00M | $423.00M | – | – |
| Onglyza | – | – | – | – | $360.00M | $470.00M | $527.00M | $543.00M | $611.00M | $720.00M | – | – |
| Arimidex | – | – | – | – | $139.00M | $185.00M | $225.00M | $212.00M | $217.00M | $232.00M | – | – |
| Atacand | – | – | – | – | $97.00M | $243.00M | $221.00M | $260.00M | $300.00M | $315.00M | – | – |
| Brilinta | – | – | – | – | $1.47B | $1.59B | $1.58B | $1.32B | $1.08B | $839.00M | – | – |
| Bydureon | – | – | – | – | $385.00M | $448.00M | $549.00M | $584.00M | $574.00M | $578.00M | – | – |
| Byetta | – | – | – | – | $55.00M | $68.00M | $110.00M | $126.00M | $176.00M | $254.00M | – | – |
| Casodex | – | – | – | – | $143.00M | $172.00M | $200.00M | $201.00M | $215.00M | $247.00M | – | – |
| Crestor | – | – | – | – | $1.10B | $1.18B | $1.28B | $1.43B | $2.37B | $3.40B | – | – |
| Daliresp/Daxas | – | – | – | – | $227.00M | $217.00M | $215.00M | $189.00M | $198.00M | $154.00M | – | – |
| Farxiga | – | – | – | – | $3.00B | $1.96B | $1.54B | $1.39B | $1.07B | $835.00M | – | – |
| Faslodex | – | – | – | – | $431.00M | $580.00M | $892.00M | $1.03B | $941.00M | $830.00M | – | – |
| FluMist/Fluenz | – | – | – | – | – | $295.00M | $113.00M | $110.00M | $78.00M | $104.00M | – | – |
| Iressa | – | – | – | – | $183.00M | $268.00M | $423.00M | $518.00M | $528.00M | $513.00M | – | – |
| Losec/Prilosec | – | – | – | – | $180.00M | $183.00M | $263.00M | $272.00M | $271.00M | $276.00M | – | – |
| Lynparza | – | – | – | – | $2.35B | $1.78B | $1.20B | $647.00M | $297.00M | $218.00M | – | – |
| Nexium | – | – | – | – | $1.33B | $1.49B | $1.48B | $1.70B | $1.95B | $2.03B | – | – |
| Total Oncology | – | – | – | – | $13.05B | $10.85B | $8.67B | $6.03B | $4.02B | $3.38B | – | – |
| Other Oncology | – | – | – | – | $50.00M | $51.00M | $94.00M | $115.00M | $114.00M | $104.00M | – | – |
| Total Other medicines | – | – | – | – | $2.37B | $2.59B | $2.60B | $3.40B | $4.16B | $5.07B | – | – |
| Other, Others | – | – | – | – | $106.00M | $126.00M | $193.00M | $290.00M | $738.00M | $920.00M | – | – |
| Other R&I | – | – | – | – | $594.00M | $398.00M | $467.00M | $545.00M | $433.00M | $316.00M | – | – |
| Pulmicort | – | – | – | – | $962.00M | $996.00M | $1.47B | $1.29B | $1.18B | $1.06B | – | – |
| BioPharmaceuticals: total Respiratory & Immunology | – | – | – | – | $6.03B | $5.36B | $5.39B | $4.91B | $4.71B | $4.75B | – | – |
| Seloken/Toprol-XL | – | – | – | – | $951.00M | $821.00M | $760.00M | $712.00M | $695.00M | $737.00M | – | – |
| Symbicort | – | – | – | – | $2.73B | $2.72B | $2.50B | $2.56B | $2.80B | $2.99B | – | – |
| Synagis | – | – | – | – | $410.00M | $372.00M | $358.00M | $665.00M | $687.00M | $677.00M | – | – |
| Eklira/Tudorza | – | – | – | – | – | – | – | $110.00M | $150.00M | $170.00M | – | – |
| Zoladex | – | – | – | – | $948.00M | $888.00M | $813.00M | $752.00M | $735.00M | $816.00M | – | – |
| CVRM | – | – | – | – | $8.02B | $7.10B | $6.91B | $6.71B | $7.27B | $8.12B | – | – |
| CVRM, Others | – | – | – | – | $196.00M | $191.00M | $271.00M | $301.00M | $339.00M | $437.00M | – | – |
| Seroquel XR/IR | – | – | – | – | $92.00M | $117.00M | $191.00M | $361.00M | $508.00M | $967.00M | – | – |
| Symlin | – | – | – | – | – | – | – | $34.00M | $48.00M | – | – | – |
| Bevespi | – | – | – | – | $54.00M | $48.00M | $42.00M | $33.00M | $16.00M | – | – | – |
| Imfinzi | – | – | – | – | $2.41B | $2.04B | $1.47B | $633.00M | $19.00M | – | – | – |
| Calquence | – | – | – | – | $1.24B | $522.00M | $164.00M | $62.00M | $3.00M | – | – | – |
| Fasenra | – | – | – | – | $1.26B | $949.00M | $704.00M | $297.00M | $1.00M | – | – | – |
| Other diabetes | – | – | – | – | $59.00M | $47.00M | $52.00M | $39.00M | $53.00M | – | – | – |
| Breztri | – | – | – | – | $203.00M | $28.00M | $2.00M | – | – | – | – | – |
| Lokelma | – | – | – | – | $175.00M | $76.00M | $14.00M | – | – | – | – | – |
| FluMist | – | – | – | – | $253.00M | $295.00M | $113.00M | – | – | – | – | – |
| Koselugo | – | – | – | – | $108.00M | $38.00M | – | – | – | – | – | – |
| COVID 19 | – | – | – | – | $4.00B | $2.00M | – | – | – | – | – | – |
| Vaxzevria | – | – | – | – | $3.92B | $2.00M | – | – | – | – | – | – |
| roxadustat | – | – | – | – | $174.00M | – | – | – | – | – | – | – |
| Enhertu | – | – | – | – | $17.00M | – | – | – | – | – | – | – |
| Total rare diseases | – | – | – | – | $3.07B | – | – | – | – | – | – | – |
| Saphnelo | – | – | – | – | $8.00M | – | – | – | – | – | – | – |
| Strensiq | – | – | – | – | $378.00M | – | – | – | – | – | – | – |
| Soliris | – | – | – | – | $1.87B | – | – | – | – | – | – | – |
| Evusheld | – | – | – | – | $85.00M | – | – | – | – | – | – | – |
| Andexxa | – | – | – | – | $68.00M | – | – | – | – | – | – | – |
| Orpathys | – | – | – | – | $16.00M | – | – | – | – | – | – | – |
| Kanuma | – | – | – | – | $62.00M | – | – | – | – | – | – | – |
| Ultomiris. | – | – | – | – | $688.00M | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Outside the UK | $54.38B | $49.33B | $42.44B | $41.23B | $34.17B | $24.88B | – | – | – | – | 92.6% | +10.2% |
| The Americas | $27.56B | $24.99B | $20.77B | $19.62B | $14.02B | $10.31B | $9.33B | $8.53B | $7.96B | $9.17B | 46.9% | +10.3% |
| United States | $23.97B | $21.81B | $18.12B | $17.28B | – | – | – | – | – | – | 40.8% | +9.9% |
| Rest of Europe | $13.46B | $11.70B | $9.73B | $8.91B | – | – | – | – | – | – | 22.9% | +15.0% |
| Asia, Africa And Australasia | $13.37B | $12.64B | $11.95B | $12.71B | $12.32B | $9.73B | $9.07B | $7.35B | $6.71B | $6.40B | 22.8% | +5.8% |
| China | $6.64B | $6.42B | $5.87B | $5.74B | – | – | – | – | – | – | 11.3% | +3.4% |
| United Kingdom | $4.36B | $4.74B | $3.37B | $3.12B | – | – | – | – | – | – | 7.4% | -8.0% |
| Others, Europe | $4.32B | $3.66B | $3.11B | $2.71B | $1.95B | $1.39B | – | – | – | – | 7.4% | +17.9% |
| Japan | $3.56B | $3.45B | $3.64B | $3.99B | – | – | – | – | – | – | 6.1% | +3.0% |
| Germany | $2.89B | $2.52B | $2.10B | $1.90B | – | – | – | – | – | – | 4.9% | +14.5% |
| Other Asia, Africa and Australasia excluding Australia, China and Japan | $2.72B | $2.33B | $2.05B | $2.41B | $2.38B | $1.53B | $1.42B | $1.31B | $1.21B | $1.22B | 4.6% | +16.8% |
| Other Americas excluding US and Canada | $2.63B | $2.25B | $1.68B | $1.18B | $1.20B | $761.00M | $814.00M | $806.00M | $809.00M | $846.00M | 4.5% | +17.2% |
| Sweden | $2.62B | $2.29B | $1.70B | $1.72B | – | – | – | – | – | – | 4.5% | +14.5% |
| France | $1.41B | $1.28B | $1.15B | $1.11B | – | – | – | – | – | – | 2.4% | +9.7% |
| Spain | $1.14B | $994.00M | $847.00M | $738.00M | – | – | – | – | – | – | 1.9% | +14.3% |
| Italy | $1.08B | $949.00M | $813.00M | $735.00M | – | – | – | – | – | – | 1.8% | +13.6% |
| Canada | $954.00M | $937.00M | $967.00M | $1.17B | – | – | – | – | – | – | 1.6% | +1.8% |
| Australia | $454.00M | $439.00M | $390.00M | $571.00M | – | – | – | – | – | – | 0.8% | +3.4% |
| UK | – | – | $3.37B | $3.12B | $3.25B | $1.74B | $1.82B | $2.39B | $3.24B | $1.85B | – | – |
| Europe | – | – | $9.73B | $8.91B | $7.83B | $4.84B | $4.16B | $3.82B | $4.56B | $5.58B | – | – |
| Sweden | – | – | $1.70B | $1.72B | $2.32B | $1.03B | $834.00M | $477.00M | $842.00M | $1.52B | – | – |
| US | – | – | $18.12B | $17.28B | $12.05B | $8.96B | $8.05B | $7.24B | $6.67B | $7.83B | – | – |
| Australia | – | – | $390.00M | $571.00M | $547.00M | $282.00M | $266.00M | $313.00M | $377.00M | $385.00M | – | – |
| Canada | – | – | $967.00M | $1.17B | $772.00M | $596.00M | $466.00M | $483.00M | $482.00M | $495.00M | – | – |
| China | – | – | $5.87B | $5.74B | $6.00B | $5.35B | $4.87B | $3.78B | $2.96B | $2.65B | – | – |
| Germany | – | – | $2.10B | $1.90B | $1.49B | $937.00M | $704.00M | $592.00M | $541.00M | $615.00M | – | – |
| Spain | – | – | $847.00M | $738.00M | $578.00M | $398.00M | $359.00M | $396.00M | $447.00M | $440.00M | – | – |
| France | – | – | $1.15B | $1.11B | $915.00M | $653.00M | $578.00M | $617.00M | $701.00M | $899.00M | – | – |
| Italy | – | – | $813.00M | $735.00M | $577.00M | $431.00M | $396.00M | $426.00M | $514.00M | $529.00M | – | – |
| Japan | – | – | $3.64B | $3.99B | $3.40B | $2.57B | $2.52B | $1.95B | $2.17B | $2.15B | – | – |
| Intra-Group | – | – | – | – | – | – | – | – | $2.45B | $3.49B | – | – |
| Intra-Group | – | – | – | – | – | – | – | – | $41.00M | $85.00M | – | – |
| Intra-Group | – | – | – | – | – | – | – | – | $3.86B | $4.11B | – | – |
| Intra-Group | – | – | – | – | – | – | – | – | $5.02B | $7.50B | – | – |
| Other continental Europe excluding Belgium, France, Germany, Italy, Spain and Sweden | – | – | – | – | $1.95B | $1.39B | $1.29B | $1.31B | $1.51B | $1.58B | – | – |
| External | – | – | – | – | $34.17B | $24.88B | $22.56B | $19.70B | $19.23B | $21.15B | – | – |
| Emerging Markets | – | – | – | – | $12.16B | $8.68B | $8.17B | $6.89B | $6.15B | $5.79B | – | – |
| Rest of World | – | – | – | – | $4.78B | $3.51B | $3.30B | $2.82B | $3.08B | $3.10B | – | – |
From the segment and revenue-disaggregation notes of Astrazeneca's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.